Skip to main content
SpringerLink
Log in

Ivacaftor not cost effective in cystic fibrosis with G551D mutation

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2019 US dollars

Reference

  • Wherry K, et al. Cost-Effectiveness of Ivacaftor Therapy for Treatment of Cystic Fibrosis Patients With the G551D Gating Mutation. Value in Health : 16 Aug 2020. Available from: URL: https://doi.org/10.1016/j.jval.2020.05.016

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ivacaftor not cost effective in cystic fibrosis with G551D mutation. PharmacoEcon Outcomes News 861, 23 (2020). https://doi.org/10.1007/s40274-020-7105-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-7105-x

Search

Navigation